Patent Application: Anti-FGFR2 Antibodies with Chemotherapy for Cancer Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Published March 26th, 2026

Detected March 26th, 2026

Summary

The USPTO has published patent application US20260085123A1, filed by Five Prime Therapeutics, Inc. The application details the use of anti-FGFR2 antibodies in combination with mFOLFOX6 chemotherapy for treating certain cancers.

View original document View source feed page

What changed

This document is a published patent application (US20260085123A1) from the USPTO, filed by Five Prime Therapeutics, Inc. It describes novel uses of antibodies targeting fibroblast growth factor receptor 2 (FGFR2), specifically the FGFR2-IIIb isoform, in conjunction with mFOLFOX6 chemotherapy for the treatment of certain types of cancer.

As this is a patent application, it does not impose direct regulatory obligations on companies. However, it signifies potential future intellectual property claims and may influence research and development strategies in the oncology sector. Companies operating in drug development and cancer treatment should be aware of this filing for competitive intelligence and potential licensing considerations.

Source document (simplified)

← USPTO Patent Applications

ANTI-FGFR2 ANTIBODIES IN COMBINATION WITH CHEMOTHERAPY AGENTS IN CANCER TREATMENT

Application US20260085123A1 Kind: A1 Mar 26, 2026

Assignee

FIVE PRIME THERAPEUTICS, INC.

Inventors

Helen L. COLLINS, James HNATYSZYN, Hong XIANG, Xiang ZHANG

Abstract

This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.

CPC Classifications

C07K 16/2863 A61K 9/0019 A61K 31/282 A61K 31/513 A61K 31/519 A61K 39/00 A61K 39/3955 A61P 35/00 A61P 35/04 A61K 2039/505 A61K 2039/545 C07K 2317/41 C07K 2317/732 C07K 2317/74 C07K 2317/76 C07K 2317/92